The invention provides compounds of the formula (3): ##STR00001##
or a pharmaceutically acceptable salt or tautomer thereof, wherein:
Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O;
ring X is a benzene or pyridine ring;
ring Y is a benzene, pyridine, thiophene or furan ring;
Ar.sup.1 is an optionally substituted benzene, pyridine, thiophene or furan ring;
m is 0, 1 or 2;
n is 0, 1 or 2;
R.sup.1 is selected from various substituents:
R.sup.2 is selected from hydrogen and a C.sub.1-4 hydrocarbon group;
R.sup.3 is selected from hydrogen and a C.sub.1-4 hydrocarbon group;
R.sup.4 is selected from various substituents;
R.sup.5 is selected from various substituents;
Ar.sup.2 is an optionally substituted phenyl, pyridyl or pyridone group;
R.sup.6 is a group Q.sup.1-R.sup.a—R.sup.b;
Q.sup.1 is absent or is a C.sub.1-3 saturated hydrocarbon linker;
R.sup.a is selected from O; C(O); C(O)O; CONR.sup.c; N(R.sup.c)CO; N(R.sup.c)CONR.sup.c, NR.sup.c; and SO.sub.2NR.sup.c;
R.sup.b is selected from hydrogen and various substituents;
and R.sup.7 is selected from R.sup.4. The compounds are useful in the treatment of cancers.

Disclosed are compounds, for example, a compound of formula I, ##STR00001##
wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

Disclosed are compounds, for example, a compound of formula I, ##STR00001##
wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.

The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.

A compound represented by the following formula (1): ##STR00001## wherein, R.sub.1 is a linear or branched alkyl group having 1 to 3 carbon atoms or a hydroxyl group; and R.sub.2 is a 1-pyrrolyl group, a 2-pyrrolyl group, or a 3-pyrrolyl group. The present invention can provide a means highly effective in contributing to savory roasting flavor and capable of imparting fragrance with natural feeling.

A compound represented by the following formula (1): ##STR00001## wherein, R.sub.1 is a linear or branched alkyl group having 1 to 3 carbon atoms or a hydroxyl group; and R.sub.2 is a 1-pyrrolyl group, a 2-pyrrolyl group, or a 3-pyrrolyl group. The present invention can provide a means highly effective in contributing to savory roasting flavor and capable of imparting fragrance with natural feeling.

The invention provides compounds of the formula (3):

##STR00001## or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar.sup.1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R.sup.1 is selected from various substituents: R.sup.2 is selected from hydrogen and a C.sub.1-4 hydrocarbon group; R.sup.3 is selected from hydrogen and a C.sub.1-4 hydrocarbon group; R.sup.4 is selected from various substituents; R.sup.5 is selected from various substituents; Ar.sup.2 is an optionally substituted phenyl, pyridyl or pyridone group; R.sup.6 is a group Q.sup.1-R.sup.a—R.sup.b; Q.sup.1 is absent or is a C.sub.1-3 saturated hydrocarbon linker; R.sup.a is selected from O; C(O); C(O)O; CONR.sup.c; N(R.sup.c)CO; N(R.sup.c)CONR.sup.c, NR.sup.c; and SO.sub.2NR.sup.c; R.sup.b is selected from hydrogen and various substituents; and R.sup.b is selected from R.sup.4. The compounds are useful in the treatment of cancers.

It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators. ##STR00001##

The present disclosure relates generally to inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.